TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31582553

Group type: EXPERIMENTAL
Intervention: Yttrium-90-labeled anti-CD45 antibody followed by fludarabine and 2 Gy total body irradiation prior to hematopoietic cell transplantation
Number of subjects: 15
Study: 31582673

Group type: EXPERIMENTAL
Intervention: Statin therapy in SP group (67.5% prescribed)
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Statin therapy in PP group (30.1% prescribed)
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol levels in SP group (18% at recommended level)
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol levels in PP group (10.6% at recommended level)
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Awareness of high cholesterol levels in SP and PP groups
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Reasons for treatment discontinuation
Number of subjects: 1868
Study: 31582991

Group type: EXPERIMENTAL
Intervention: Microfragmented dermal extract obtained with Rigenera™ technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31583112

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) device (LymphAssist, Huntleigh Healthcare)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 31583172

Group type: EXPERIMENTAL
Intervention: Implanted seizure prediction system (NCT01043406)
Number of subjects: 0
Study: 31583331

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study: 31583470

Group type: EXPERIMENTAL
Intervention: Indoor air quality indices (CO)
Number of subjects: 0
Study: 31583561

Group type: EXPERIMENTAL
Intervention: Supraphysiologic doses of levothyroxine (L-T4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31584000

Group type: EXPERIMENTAL
Intervention: iCBT (internet-based cognitive behavioral therapy) program for 9 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: ODF (online discussion forum)
Number of subjects: 144
Study: 31584004

Group type: EXPERIMENTAL
Intervention: Integrated wellness care clinics and SHIELD intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Only SHIELD intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control zones with no intervention
Number of subjects: 0
Study: 31584094

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no SMC)
Number of subjects: 0
Study: 31584608

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily in c-MET ≥6 copies cohort
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily in c-MET mutation cohort
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily in ROS-1 translocation cohort
Number of subjects: 90
Study: 31584770

Group type: EXPERIMENTAL
Intervention: Prospective period for any hypoglycemia (T1D)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Retrospective period for any hypoglycemia (T1D)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Prospective period for any hypoglycemia (T2D)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Retrospective period for any hypoglycemia (T2D)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Prospective period for severe hypoglycemia (T1D)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Retrospective period for severe hypoglycemia (T1D)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Prospective period for severe hypoglycemia (T2D)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Retrospective period for severe hypoglycemia (T2D)
Number of subjects: 664
Study: 31585005

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 402
Study: 31585012

Group type: EXPERIMENTAL
Intervention: PLMS with arousal
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Arousals associated with PLMS
Number of subjects: 49

Group type: COMPARATOR
Intervention: PLMS without arousal
Number of subjects: 49
Study: 31585957

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) and selective hedgehog pathway inhibitor vismodegib
Number of subjects: 1
Study: 31586174

Group type: EXPERIMENTAL
Intervention: Caregivers' illness representations (IRs) aligned with the professional model of asthma management.
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Structural equation model results.
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Social/contextual predictors of asthma illness representations (IRs).
Number of subjects: 267
Study: 31586493

Group type: EXPERIMENTAL
Intervention: Greater GLP-1 response
Number of subjects: 837

Group type: COMPARATOR
Intervention: Greatest quartile of GLP-1 response
Number of subjects: 837
Study: 31586664

Group type: EXPERIMENTAL
Intervention: Concurrent cetuximab (400 mg/m2) and intensity modulated radiation therapy with carbon ion boost
Number of subjects: 23
Study: 31586667

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 0
Study: 31586757

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (GV) 1.9 mg/kg/dose administered on day 1 of each 21 day cycle.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (GV)
Number of subjects: 22
Study: 31586998

Group type: EXPERIMENTAL
Intervention: Treatment in patients <70 years old
Number of subjects: 866

Group type: COMPARATOR
Intervention: Treatment in patients ≥70 years old
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Overall survival in patients <70 years old
Number of subjects: 866

Group type: COMPARATOR
Intervention: Overall survival in patients ≥70 years old
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Age as a factor in overall survival
Number of subjects: 866
Study: 31587120

Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography (EIT) measures during PEEP trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different EIT measures
Number of subjects: 0
Study: 31587882

Group type: EXPERIMENTAL
Intervention: Lazertinib (20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lazertinib
Number of subjects: 127
Study: 31588013

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study: 31588425

Group type: EXPERIMENTAL
Intervention: Neonatal iron distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection susceptibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31588493

Group type: EXPERIMENTAL
Intervention: 1 mg/kg liposomal amphotericin B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 mg/kg liposomal amphotericin B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fixed dose of 300 or 500 mg liposomal amphotericin B for patients ≥100 kg
Number of subjects: 16
Study: 31588494

Group type: EXPERIMENTAL
Intervention: Liothyronine every 8 hours for 2 weeks (n = 7)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Liothyronine after 6 months (n = 4)
Number of subjects: 7
Study: 31588567

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg plus low-dose dexamethasone (40 mg or 20 mg for patients aged >75 years)
Number of subjects: 56
Study: 31588660

Group type: EXPERIMENTAL
Intervention: IMPROD bpMRI Likert score
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical variables
Number of subjects: 80

Group type: COMPARATOR
Intervention: mRNA biomarkers
Number of subjects: 80

Group type: COMPARATOR
Intervention: Additional IMPROD bpMRI parameters
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of clinical and mRNA biomarkers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Qualitative IMPROD bpMRI Likert score
Number of subjects: 80
Study: 31588864

Group type: EXPERIMENTAL
Intervention: High-carbohydrate challenge
Number of subjects: 72
Study: 31588872

Group type: EXPERIMENTAL
Intervention: Supervised endurance training for 10 weeks
Number of subjects: 0
Study: 31589281

Group type: EXPERIMENTAL
Intervention: Patient Priorities Care (PPC)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 366
Study: 31589465

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Other nonwhite patients
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 3202
Study: 31589625

Group type: EXPERIMENTAL
Intervention: e-partograph
Number of subjects: 1012

Group type: COMPARATOR
Intervention: paper partograph
Number of subjects: 1012
Study: 31590067

Group type: EXPERIMENTAL
Intervention: Dynamic Gait Index (DGI)
Number of subjects: 32
Study: 31590634

Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment in patients with sufficient performance validity (239 patients)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment in patients with insufficient performance validity (40 patients)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires administered to measure cognitive complaints, fatigue, anxiety, depressive symptoms
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Comparison of cognitive test scores to a normative sample
Number of subjects: 279
Study: 31590677

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Personalization algorithm using clinical pretreatment data
Number of subjects: 54
Study: 31591361

Group type: EXPERIMENTAL
Intervention: Hysteroscopic diagnosis of Endometrial Hyperplasia (EH) by senior gynecologists
Number of subjects: 0
Study: 31591599

Group type: EXPERIMENTAL
Intervention: Vaginal microbiome transplantation (VMT) from healthy donors
Number of subjects: 5
Study: 31591636

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) in postmenopausal patients
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) in premenopausal patients
Number of subjects: 4262
Study: 31591739

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine
Number of subjects: 0
Study: 31592575

Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninsured participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insured participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older age and STI diagnosis
Number of subjects: 0
Study: 31592772

Group type: EXPERIMENTAL
Intervention: Home-based aerobic and strengthening exercises during preoperative chemotherapy or chemoradiation
Number of subjects: 50
Study: 31592894

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 5577

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 5577

Group type: EXPERIMENTAL
Intervention: Both RYGB and SG
Number of subjects: 5577
Study: 31592901

Group type: EXPERIMENTAL
Intervention: Thermochromic nail polish
Number of subjects: 50
Study: 31592900

Group type: EXPERIMENTAL
Intervention: Flexor hallucis brevis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adductor pollicis
Number of subjects: 60
Study: 31593308

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day for a minimum of 9 days, mean 13.6 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study: 31593552

Group type: EXPERIMENTAL
Intervention: miR-16 overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVs from MM-PCs with Del13
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-15a-16-1-KO mouse model
Number of subjects: 0
Study: 31593563

Group type: EXPERIMENTAL
Intervention: Asymptomatic Leishmania infection detected using DAT, rK39-RDT, PCR, and KAtex urine antigen test.
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Follow-up of prevalent infections.
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Overall study follow-up.
Number of subjects: 511
Study: 31594030

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31594647

Group type: EXPERIMENTAL
Intervention: ACHIM (anaerobic cultivated human intestinal microbiota) administered via upper gastrointestinal route using endoscopy for 10 days
Number of subjects: 50
Study: 31594667

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) treatment
Number of subjects: 460

Group type: COMPARATOR
Intervention: Sofosbuvir/velpatasvir (SOF/VEL)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Glecaprevir/pibrentasvir (GLE/PIB)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Ledipasvir/sofosbuvir (LDV/SOF)
Number of subjects: 460
Study: 31594705

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 211

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 211
Study: 31595258

Group type: EXPERIMENTAL
Intervention: Nursing care intervention centered on basic self-care including twice daily walking training, privileging pre-established trips to the toilet by walking, and all daytime meals seated, off the bed.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 182
Study: 31595259

Group type: EXPERIMENTAL
Intervention: Intervention program comprising 3 weekly classes of physical exercise (45/50 min each) delivered by trained teachers after teachers' training by researchers.
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard care provided by health professionals.
Number of subjects: 410
Study: 31595353

Group type: EXPERIMENTAL
Intervention: POCUS (Point-of-care ultrasound)
Number of subjects: 80
Study: 31595377

Group type: EXPERIMENTAL
Intervention: Conversation more than 20 minutes
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Covering many topics
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Presence of a significant other
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 386

Group type: COMPARATOR
Intervention: Not receiving a specific diagnosis
Number of subjects: 386
Study: 31595482

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 1060
Study: 31595670

Group type: EXPERIMENTAL
Intervention: Prophylaxis treatment in hemophilia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemophilia
Number of subjects: 0
Study: 31595793

Group type: EXPERIMENTAL
Intervention: Dosage-controlled cannabis capsules; specific dosage and duration not available
Number of subjects: 0
Study: 31595982

Group type: EXPERIMENTAL
Intervention: Calcimimetic treatment (30-60 mg daily for 4 weeks)
Number of subjects: 110
Study: 31596034

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 40
Study: 31597157

Group type: EXPERIMENTAL
Intervention: Less intensive chemotherapy with autotransplant
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Autotransplant
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: White blood cells ≥100 × 10^9/L at study entry
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Receiving an autotransplant
Number of subjects: 125
Study: 31598047

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg sublingually as premedication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31598139

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg orally once daily
Number of subjects: 3480
Study: 31598346

Group type: EXPERIMENTAL
Intervention: Early rehabilitation protocol with a short-term immobilization period of 2 weeks.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional protocol with immobilization of the shoulder for over 4 weeks.
Number of subjects: 115
Study: 31598646

Group type: EXPERIMENTAL
Intervention: Flublok (recombinant protein-based)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Flucelvax (cell-based)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fluzone (egg-based)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fluzone High-Dose (egg-based)
Number of subjects: 85
Study: 31599001

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 31599480

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen (RIC) containing alemtuzumab, fludarabine, melphalan, and thiotepa
Number of subjects: 4
Study: 31599736

Group type: EXPERIMENTAL
Intervention: Human-centered design (HCD) methods applied to evidence-based psychosocial interventions (EBPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iteratively designed solutions to usability challenges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stakeholder involvement in design of EBPI modifications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCD-informed modifications and solutions
Number of subjects: 0
Study: 31599928

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (1 g/L in drinking water for 7 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (10 μmol/min infusion for 30 minutes)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vehicle (0.9% saline)
Number of subjects: 2
Study: 31599951

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 48
Study: 31600167

Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine (150 mg bid)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine (300 mg bid)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine (450 mg bid)
Number of subjects: 11
Study: 31601186

Group type: EXPERIMENTAL
Intervention: Cynomolgus macaques
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy humans
Number of subjects: 12
Study: 31601199

Group type: EXPERIMENTAL
Intervention: EQUIP organizational intervention to promote equity in health care
Number of subjects: 0
Study: 31601588

Group type: EXPERIMENTAL
Intervention: Maternal night-eating pattern (consumption of meal and snack during 1900-0659 hours)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring at 18-24 weeks' gestation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test and insulin test at 24-28 weeks' gestation
Number of subjects: 200
Study: 31601596

Group type: EXPERIMENTAL
Intervention: Oral glyburide administered within 8 hours of injury
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral glyburide
Number of subjects: 10
Study: 31601602

Group type: EXPERIMENTAL
Intervention: Automated early warning system (EWS) - Rothman Index by PeraHealth
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Physician judgement
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Combined model of physician and EWS predictions
Number of subjects: 1874
Study: 31601604

Group type: EXPERIMENTAL
Intervention: Strengthened growth monitoring and promotion (GMP) activities in community clinics (CCs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention to strengthen GMP implementation in community clinics (CCs)
Number of subjects: 30
Study: 31601646

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection with indocyanine green
Number of subjects: 176
Study: 31601692

Group type: EXPERIMENTAL
Intervention: Treatment according to AIEOP-BFM protocols
Number of subjects: 0
Study: 31601728

Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m
Number of subjects: 10003
Study: 31602237

Group type: COMPARATOR
Intervention: Sphingolipid metabolites measurement (So1P, GluCer, SM, Sa, So)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: So1P and Sa
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 245
Study: 31602320

Group type: EXPERIMENTAL
Intervention: FoundationACT™ ctDNA assay (Foundation Medicine, Cambridge, MA, USA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comprehensive genomic profiling (CGP) of tumor tissue sample
Number of subjects: 96
Study: 31602518

Group type: EXPERIMENTAL
Intervention: Open abdomen treatment in obese patients
Number of subjects: 591
Study: 31602644

Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Number of subjects: 63
Study: 31603393

Group type: EXPERIMENTAL
Intervention: Financial barriers (no insurance and underinsurance)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Peripheral Artery Questionnaire (PAQ)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: EuroQol 5 (EQ5D) dimensions
Number of subjects: 797
Study: 31603563

Group type: EXPERIMENTAL
Intervention: Olfactory cleft (OC) opacification in CRS patients (average 63.7%)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Olfactory cleft (OC) opacification in control subjects (average 47.1%)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: CRSwNP patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: CRSsNP patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lund-Mackay score in CRSsNP patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lund-Mackay score in CRSwNP patients
Number of subjects: 148
Study: 31604171

Group type: EXPERIMENTAL
Intervention: CT-assessed VAT volume
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SAT volume
Number of subjects: 44
Study: 31604419

Group type: EXPERIMENTAL
Intervention: Propofol induction dose based on total body weight (TBW) scaled by phase angle value
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Guiding propofol induction dose according to baseline frailty score
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Determination of phase angle value
Number of subjects: 40
Study: 31604778

Group type: EXPERIMENTAL
Intervention: Heterozygous variants in DNA damage repair genes
Number of subjects: 0